Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03927703
Other study ID # NI-MC302
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 13, 2019
Est. completion date February 3, 2020

Study information

Verified date March 2023
Source Novan, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.


Description:

This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in approximately 340 subjects with MC. After obtaining informed consent/assent, subjects who satisfy entry criteria will be randomized 2:1 (active:vehicle). Subjects receiving current treatment for MC at the time of the Screening Visit will enter a wash out period of up to 14 days prior to randomization. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study. Subjects or their caregivers will continue to treat the area until the next scheduled visit even if the lesion(s) clear. If the investigator determines all lesions are cleared at a clinic visit, the treatment may stop. Subjects will visit the clinic at Screening/Baseline, Week 2, Week 4, Week 8, Week 12. In addition, subjects will be seen in the clinic for a safety follow-up at Week 24.


Recruitment information / eligibility

Status Completed
Enrollment 355
Est. completion date February 3, 2020
Est. primary completion date November 11, 2019
Accepts healthy volunteers No
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria: - Be 6 months of age or older, and in good general health; - Have a written informed consent form signed by subject or a parent or legal guardian and an assent form as required; - Have between 3 and 70 treatable MC at Baseline; - Female subjects age 9 and above must have a negative UPT at Baseline; - Female subjects age 9 and above must agree to practice a medically acceptable form of birth control during the study and for 30 days after Week 12/ET1; - Be willing and able to follow study instructions and likely to complete all study requirements. Exclusion Criteria: - Have strongly suggested sexually transmitted MC and do not agree to refrain from sexual activities throughout the study period. - Are immunosuppressed, have immunodeficiency disorder, or are on immunosuppressive treatment; - Have significant injury on and/or surrounding MC that may impact ability to treat and count lesions; - Have received treatment with topical calcineurin inhibitors or steroids on MC or within 2 cm of MC lesions within 14 days prior to Baseline; - Have received treatment for MC during the 14 days prior to Baseline with podophyllotoxin, imiquimod, cantharidin, sinecatechins, topical retinoids, oral or topical zinc, or other homeopathic or over the counter (OTC) products including, but not limited to, ZymaDerm and tea tree oil, cimetidine and other histamine H2 receptor antagonists (including Zantac); - Have received surgical procedures related to MC (cryotherapy, curettage, other) within 14 days prior to Baseline; - Have MC only in periocular area; - Female subjects who are pregnant, planning a pregnancy or breastfeeding; - Have known hypersensitivity to any ingredients of SB206 or Vehicle Gel including excipients; - Have participated in a previous study with a berdazimer sodium product (SB204, SB206, SB208, SB414); - Have more than 1 family member currently participating in a study with a berdazimer sodium product (SB204, SB206, SB208, SB414). - Have participated in any other trial of an interventional investigational drug or device within 14 days or concurrent participation in another interventional research study. - History or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SB206 12%
Topically once daily
Placebo
Topically once daily

Locations

Country Name City State
United States Site #201 Berlin New Jersey
United States Site #282 Beverly Hills California
United States Site #268 Boynton Beach Florida
United States Site #274 Clarkston Michigan
United States Site #292 DeLand Florida
United States Site #121 Fridley Minnesota
United States Site #101 Hot Springs Arkansas
United States Site #167 Houston Texas
United States Site #271 Knoxville Tennessee
United States Site #275 Largo Maryland
United States Site #289 Metairie Louisiana
United States Site #278 Miami Florida
United States Site #255 Mount Pleasant South Carolina
United States Site #175 New Albany Indiana
United States Site #297 New Orleans Louisiana
United States Site #206 Omaha Nebraska
United States Site #294 Owensboro Kentucky
United States Site #293 Plano Texas
United States Site #309 Portland Oregon
United States Site #304 Portsmouth New Hampshire
United States Site #267 Richmond Virginia
United States Site #108 Rochester New York
United States Site #113 San Diego California
United States Site #266 Scottsdale Arizona
United States Site #281 Syracuse Utah
United States Site #305 Tampa Florida
United States Site #257 Thornton Colorado

Sponsors (2)

Lead Sponsor Collaborator
Novan, Inc. Synteract, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete Clearance of All Treatable MC at Week 12 Percent (proportion) of subjects with complete clearance of all treatable MC at Week 12. This was measured by dividing the number of subjects who showed complete clearance by the number in that treatment group (this represents our primary outcome variable). 12 Weeks
Secondary Complete Clearance of All Treatable MC at Week 8 Percent (proportion) of subjects with complete clearance of all treatable MC at Week 8. This was measured by dividing the number of subjects who showed complete clearance at week 8 by the number in that treatment group (this represents our secondary outcome variable). 8 Weeks
See also
  Status Clinical Trial Phase
Completed NCT03017846 - Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 Phase 2
Recruiting NCT05937672 - Cold Atmospheric Plasma Device Extension Study Phase 3
Completed NCT04535531 - A Phase 3 Molluscum Contagiosum Efficacy and Safety Study Phase 3
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT05897112 - Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum Phase 1
Withdrawn NCT05536882 - MC RCT - BPO vs Adapalene Phase 3
Completed NCT03377790 - Cantharidin Application in Molluscum Patients-1 Phase 3
Completed NCT01348386 - Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum Phase 2/Phase 3
Completed NCT05634460 - Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum Phase 1
Completed NCT03186378 - Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. Phase 2
Completed NCT03927716 - A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) Phase 3
Recruiting NCT04476186 - The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children N/A
Completed NCT02665260 - Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03436615 - A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum Phase 2
Recruiting NCT02759900 - Using a Cold Atmospheric Plasma Device to Treat Skin Disorders N/A
Completed NCT05680181 - Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
Completed NCT03077750 - A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum Phase 2
Terminated NCT02024581 - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03377803 - Cantharidin Application in Molluscum Patients Phase 3
Withdrawn NCT03336372 - Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients Early Phase 1